Table 5

Age-stratified analysis of lifetime risk of ovarian cancer associated with BRCA1 mutations

SEER adjusted incidence rateaCarrier prevalenceRelative riskCarrier incidence ratePenetranceb (95% CI)
185delAG
20–29 yrs0.00040.01346.00.0111% (0.4–3%)
30–39 yrs0.00080.01346.00.0223% (1–8%)
40–49 yrs0.00170.00884.80.08712% (7–25%)
50–59 yrs0.00320.002117.90.31139% (23–100%)
60–69 yrs0.00450.002117.90.43666% (37–100%)
70–79 yrs0.00580.002117.90.56585% (53–100%)
80+ yrs0.00570.002117.90.54993% (63–100%)
5382insC
20–29 yrs0.00040.00325.90.0101% (0–5%)
30–39 yrs0.00080.00325.90.0193% (0–14%)
40–49 yrs0.00170.003109.00.14617% (6–55%)
50–59 yrs0.00320.00420.60.06222% (11–60%)
60–69 yrs0.00450.00420.60.08729% (16–69%)
70–79 yrs0.00580.00420.60.11237% (22–78%)
80+ yrs0.00570.00420.60.10944% (29–86%)
  • a The adjusted incidence rates (Ra*) from Table 3<$REFLINK> .

  • b Penetrance is the probability of a mutation carrier developing ovarian cancer by the end of the age interval.